Tag: Cellular Treatment

Sep
25
2018
What is Ataxia?
“Ataxia. It’s like Multiple Sclerosis ganged up with Parkinson’s and played a dirty trick on Cerebral Palsy.” This is a headline on the poster from Awareness Day UK, which reflects the complications of the disease. Although the disease is a rare condition, those inflicted with it as well as their families and loved ones, suffer unimaginable pain.
Ataxia is a rare group of neurological condition attacking the brain and has serious effects on the patients’ balance, coordination, and speech. There are different types of Ataxia and it may affect all groups of people in different age range and currently has no cure. The disease also comes with other debilitating conditions including diabetes and heart diseases.
Currently, specific treatments are provided to patients to help relieve their symptoms and improve their well-being. Doctors recommend Speech therapy, Physical Therapy, and Occupational Therapy to help patients carry out their day- to- day chores.
Spreading Awareness of Ataxia
International Ataxia Awareness Day (IAAD) is celebrated every year on 25th September, where everyone can help raise awareness of the disease. The more people are aware of Ataxia, the more research may be invested to discover a treatment for this incurable disease. According to Awareness Day UK, only ten percent of the population in the United Kingdom knows this disease. However, there are many ways to spread awareness of this disease, including speaking in local communities, schools, and society groups. The IAAD also helps to raise funds for the National Ataxia Foundation (NAF) research studies and clinical trials to help patients get treatment for this condition.
For those concerned with the disease or would like to help, there are simple ways to help spread the word on Ataxia. You can download a poster from Awareness Day UK here and ask permission to put them up on your workplace, school, hospitals, or home. There are also handy flyers and a booklet with an outline of the condition and details of the disease which you can download and pass them onto your community.
Stem Cell Treatment for Ataxia at Unique Access Medical
One innovative treatment for Ataxia is Regenerative Treatment, which has also treated other incurable diseases like Cerebral Palsy, Autism, Multiple Sclerosis, Stroke and many Autoimmune Diseases. Doctors and researchers believe that the treatment imposes the least risks for patients and enhances the patient’s conditions progressively.
Unique Access Medical partners with internationally accredited hospitals to provide safe and successful treatments for patients. Treatment programs are carried out by highly qualified doctors, therapists and personnel to ensure the most advantageous result for the patients. Unique Access provides access to an extensive treatment protocol for Ataxia which utilises higher quantities of regenerative cells, innovative cell growth factors, extensive rehabilitation, and many supportive therapies and supplements. This effective combination of the most advanced medical technologies with functional medicine has helped patients achieve significant improvements.

H/T: Ataxia UK
Global Stem Cells September 25, 2018 September 25, 2018
Tags:
Ataxia Awareness
Cellular Treatment
Stem Cell Research
Stem Cell Treatment
Categories:
Misc.
Sep
24
2018
Jacob Glasow, 36, was diagnosed with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease on July 12, 2018. Due to the condition of the disease, like many patients of ALS, Glasow had difficulties speaking. He observed changes in his speech including his arms and leg muscles twitching. He also noticed that his smile became slightly lopsided. After being admitted to the hospital to undergo Lumbar Puncture Stem Cell Infusion this August, he felt much happier with significant improvement, especially in his speaking abilities.
Please see Glasow’s before and after clip:
Before the treatment
At first, Glasow thought he had sleep apnea due to his slurred speech and muscle spasms. He then scheduled a doctor’s appointment which led to a Magnetic Resonance Imaging (MRI) referral, in which doctors at his hometown found some abnormalities in his brain. After MRIs and an Electromyography (EMG), Glasow’s diagnosis of ALS was confirmed.
Glasow’s wife, Sheena, contacted Unique Access Medical in July and travelled with Glasow to get the treatment in Bangkok, Thailand.
After receiving Amniotic Fluid Stem Cell through his first Lumbar Puncture Stem Cell Infusion on August 21, 2018, he noticed remarkable improvement in his speech. His speech became much more smoother and more fluent.
Glasow’s improvement after Lumbar Puncture Stem Cell Infusion.
Along with Regenerative Stem Cell Therapy, Glasow also received five hours of Occupational Therapy, four hours of Physical Therapy, five hours of Transcranial Magnetic Stimulation (TMS) sessions, and three aqua sessions. Now, he is back home and is continuing with his Occupational Therapy program, using the lessons he’s learnt from UAM’s therapists.
Check clip of Glasow playing with his son.
All of our patient’s family and friends have the freedom to enjoy Bangkok city. Glasow and his wife said they had a comfortable stay in the hospital and a great time indulging in street food by the riverside, weekend markets, and floating market.
Glasow is a volunteer firefighter from Reedsville, Wisconsin. He has been married to Sheena for five years and has five children. His significant improvement regarding speech has brought great happiness to his family.
About Amyotrophic Lateral Sclerosis:
MND identifies a group of diseases that affect the nerve cells, especially motor neurons in the brain and spinal cord. These neurons that control movement gradually fail to reach the muscles, causing the muscles to weaken and stiffen, rendering them useless. Muscles that control speaking, swallowing, and breathing also stop working. MND usually affects people from 50 years and older, but occasionally younger people may be inflicted with it. Life expectancy is between two and five years. MND is also called amyotrophic lateral sclerosis (ALS) in the United States, South America, and Canada. Another common name for it is Lou Gehrig’s Disease after a baseball player who died from the disease in 1941.
To learn more about Lumbar Puncture Stem Cell Injections please click here.
Global Stem Cells September 24, 2018
Tags:
Cellular Treatment
Stem Cell Research
Stem Cell Treatment
Categories:
Misc.
Sep
19
2018
Congenital birth defects may be treated by using amniotic fluid, the protective liquid surrounding an unborn baby often discarded as waste during caesarean deliveries . Over the past decade, studies have shown that this fluid is a valuable source for deriving stem cells and is an emerging possibility for Cell Therapy or Regenerative Medicine. Amniotic fluid is also a source for Mesenchymal Stem Cells (MSCs), also called a multipotent tissue or adult stem cell which can produce more than one type of specialized cell, useful in treating different diseases such as cardiovascular disease, diabetes, arthritis, and neurodegenerative disorders.
According to the research by Shuan M. Kunisaki, Amniotic Fluid Stem Cells for the Treatment of Surgical Disorders in the Fetus and Neonate, amniotic fluid-derived stem cells have been the source of inspiration for experimental approach which aims at improving treatment for birth defects in a newborn. Popularity of the study of these fetus cells, also called amniocytes, for prenatally diagnosed diseases were based on several studies that prove its unique properties and their beneficial effects tested on animals models.Some of the emerging Cell Therapy resulting from the study of amniotic fluid, includes spina bifida treatment and treatment for birth heart defects. Currently, amniotic fluid based-stem cell technologies has been used with the fabrication of tissue-engineered heart valves which could lead to treatment for birth heart defects.
There are several reasons why amniotic fluid-derived stem cells are becoming one of the breakthrough approaches
in treating children with congenital anomalies or birth defects. According to Kunisaki’s thesis, one of the reason is that there is no need to wait until delivery for cell harvesting since amniocytes are easily accessible through the process of amniotic fluid test. During this process, a small amount of amniotic fluid is removed from the sac surrounding the fetus for testing. Contrasted to the traditional method of harvesting stem cells prenatally from placenta, chorionic villi, cord blood, liver or skin, the amniotic fluid test procedure is less challenging and has smaller risks of abortion, infection, hemorrhage, and other morbidities.
Another fact amniotic fluid-derived stem cells is gaining more attention is that MSCs can be obtained from other tissues in the body, however, the difficulty in acquiring an abundant number of cells limits its use in Cell Therapy and tissue repair applications, according to Lund University. “Full term amniotic fluid, being an easily obtainable and abundant tissue source, may be the solution for MSC based cell therapy and regenerative medicine applications”, said Associate Professor Niels-Bjarne Woods, a corresponding author of a study done by scientists and clinicians at Lund University in Sweden. Amniotic fluid-derived stem cells comes from the fetus itself, therefore it can be used in Stem Cell Therapy without the concern for immunologic rejection of donor cells or the rejection by the recipient’s immune system. In fact, Kunisaki wrote that the safety with amniocentesis is causing a rise in commercial banking of amniotic fluid in developed countries.

H/T: Lund University
Global Stem Cells September 19, 2018 September 19, 2018
Tags:
Cellular Treatment
Stem Cell Research
Stem Cell Treatment
Categories:
Misc.
Sep
11
2018
Researchers in Japan have uncovered a breakthrough Stem Cell Treatment for parkinson’s disease, reported Science Immunology. The procedure involves reprogramming induced pluripotent stem (iPS) cells and injecting dopaminergic progenitors, a cell type that develops into dopamine-producing neurons into the forebrain. This discovery of parkinson’s Stem Cell Treatment by Jun Takahashi, a neurosurgeon at Kyoto University’s Center for iPS Cell Research and Application (CiRA), is based on reviving depleted specialized cells in the brain responsible for producing neurotransmitter dopamine. Parkinson’s disease is caused by the depletion of dopamine in the brain, which disables motor skills, thus resulting in difficulties walking as well as trembling, and if left untreated could cause dementia.
The researchers found Stem Cell Therapy for parkinson’s disease in which they could take neurological material from iPS cells or mature cells that can be chemically manipulated to return to its embryonic stem- cell like stage and become differentiated into any of the body’s specialized cells, according to Science Immunology.
Parkinson’s disease stem cell clinical trials are based on the derivation of dopaminergic progenitors, the dopamine-producing neurons, from iPS cells and injecting them into the putamen, a round structure located at the base of the forebrain. Two small holes are drilled by surgeons through the patient’s skull, with a specialized device injecting around five million cells. The parkinson’s Stem Cell Treatment was also used in animals, whereby dopaminergic neurons was found to differentiate into progenitors inside the body and inserted into the brain. The researchers reported in 2017 that monkeys with parkinson’s disease showed significant improvement after getting injections of neurons taken from human iPS cells, lasting for two years.
Rather than make a specific iPS cells for each patient, CiRA researchers instead took stocks of iPS cells from healthy donors with specific cell types. “Using stocks of cells, we can proceed much more quickly and cost-effectively,” CiRA Director Shinya Yamanaka, who discovered how to create iPS cells, told Science in 2017. To counter the risk of immune rejection, all patients will receive a common immunosuppressant in along with the progenitors.
The stem cell research for parkinson’s disease was the third human trial using iPS cells approved in Japan. The first was researched in 2014 by using retinal cells derived from iPS cells to replace eye tissue damaged by age-related macular degeneration (AMD), led by Masayo Takahashi, Jun Takahashi’s wife of the RIKEN Center for Developmental Biology in Kobe. The AMD treatment was reported to be safe with one case reporting adverse effects. Another team at Osaka University in Japan won conditional approval for the first clinical study iPS cell–based study for treating heart failure in May.
Currently, there are no cures for Parkinson’s disease, but drugs and deep brain stimulation are some of the methods currently used to alleviate symptoms.

H/T: Science Mag
Global Stem Cells September 11, 2018
Tags:
Cellular Treatment
Stem Cell Research
Stem Cell Treatment
Categories:
Misc.
Aug
29
2018
Patients with Multiple Sclerosis (MS) can walk, run, and even dance again following a new stem cell treatment that allows the immune system to be rebooted again. Doctors described the treatment as ‘miraculous’ as reported by The Sunday Times. However, there are still some dangerous factors to the treatment which involves intense chemotherapy and patients are advised to be physically fit.
The cause of MS is still unknown, however doctors believe that the culprit is the immune system attacking the brain and spinal cord leading to inflammation and pain, disability and in the worst cases, death.
The process of this new Stem Cell Treatment involves harvesting and storing the patients’ stem cells and the use of chemotherapy. Following the administration of chemotherapy, which is aimed to deplete the body’s immune system, those harvested stem cells are then infused back into the patients, giving the immune system a chance to regenerate and repair itself. A month after which, patients are starting to notice signs of recovery. The new therapy is called Autologous Haematopoietic Stem Cell Transplantation (HSCT) and paired with intensive rehabilitation and physiotherapy so that patients can learn to walk again.
Professors Basil Sharrack, a neurologist, and John Snowden, a haematologist, reported the results in The Journal of the American Medical Association.
“Since we started treating patients some three years ago, some of the results we have seen have been miraculous,” said Sharrack to The Sunday Times. “This is not a word I would use lightly, but we have seen profound neurological improvements.”
“This is not a treatment suitable for everybody because it is very aggressive and patients need to be quite fit to withstand the effects of the chemotherapy,” he added.
The experiment involves two dozen patients taking part in trials at the Royal Hallamshire Hospital in Sheffield and Kings College, Hospital, London. One of the patients in the test named Sam Ramsey, 29, a former care assistant from Newark, Nottinghamshire, was the first UK patient to be treated. She was paralysed from the neck down by MS and had to use a ventilator to help her breathe.
“I was so ill I can barely remember being on a ventilator,” Ramsey said to the The Sunday Times. “But I can remember a couple of weeks after the transplant, my sister went running around the room when my fingers started to move again. As the days went by my toes started to wiggle. I was getting the feeling back in my limbs.”
Another patient, Holly Drewry, 25, of Sheffield, was wheelchair- bound after suffering from MS after the birth of her daughter.
“After the birth I went downhill really quickly and was in a wheelchair, barely able to feel my toes,” Drewry said to The Sunday Times, “It worked wonders. After three weeks, I called my mum and said, ‘I can stand!’ We were all crying. Now I can run a little bit, I can dance. I enjoy walking my daughter around the park in her pram.”

H/T: Telegraph UK
Global Stem Cells August 29, 2018
Tags:
Cellular Treatment
Stem Cell Research
Stem Cell Treatment
Categories:
Misc.
Aug
21
2018
Researchers at the University of California (UC) San Diego School of Medicine reported promising results of the phase I of the clinical trial, where Stem Cells were transplanted into four chronic Spinal Cord Injury patients, with conditions ranging from injuries at a T2 to T12 thoracic level. Each received a total of six injections of 1.2 million stem cells and yielded encouraging improvements.
This clinical research is the first trial on human. Considered an advancement in the field of Regenerative Medicine, it is performed subsequently to the previous successful transplantation of Stem Cells in rats with Spinal Cord Injuries, which resulted in improvement in the rodents’ mobility, functioning, as well as neuronal regeneration.
“The primary purpose of this first trial was to assess safety. And no procedure-related complications were observed in any of the patients,” said Joseph Ciacci, MD, the principal investigator and a neurosurgeon at UC San Diego Health. Instead, three of the four patients who underwent the clinical trial saw improvements in their motor and sensory functions and experienced no serious side effects.
“Our results suggest the approach can be performed safely. These early signs of potential efficacy [of the stem cells], combined with the promising results of earlier animal studies, argue for pressing ahead with new trials and greater doses to see if we can further accelerate repair and recovery,” he continued.
Fueled by the encouraging results, researchers at University of California San Diego prepares for the development of the second clinical trial, whose focus will be on cervical level injuries.

H/T: UC San Diego Health
Global Stem Cells August 21, 2018 August 22, 2018
Tags:
Cellular Treatment
Stem Cell Research
Stem Cell Treatment
Categories:
Misc.
Aug
15
2018
Mesenchymal Stem Cells and Its Benefit in Stem Cell Therapy
The U.S Food & Drug Administration (FDA) had been developing methods that would help them discover how manufactured or isolated Mesenchymal Stem Cells (MSCs) behave in patients. MSCs are discovered to have the ability to protect, restore, or repair tissues in the body, becoming an important part of Regenerative Medicine. Therefore, the ability to predict specific functions of different preparations of MSCs in the lab could be a big leap toward creating safe and effective FDA-approved treatments for patients.
MSCs, also called a multipotent tissue or adult stem cell, can produce more than one type of specialized cell of the body but not all types of cells. Their skills are limited to specialized cells that are found in skeletal tissues including cartilage cells, bone cells, and fat cells. MSCs may also help the body control inflammation by suppressing immune cell functions, also called immunosuppression.
The Problem with MSCs
According to FDA’s research, MSCs are found to be responsive to their environment. However, in a lab-based manufacturing process, MSCs are not tested on the body, and therefore could react in unexpected ways when it is put into a patient. For example, they might not suppress inflammation well, might form wrong tissues in a place where it is not needed, and even form tumors, according to U.S Food & Drug Administration’s article.
Morphological Profiling to Predict Outcomes in MSCs
In an effort to prevent MSCs yielding undesirable effects, FDA had researched ways to predict cells’ behavior or whether stimulated MSCs are going to differentiate into specific cells that can do specific tasks. This approach is called functionally-relevant morphological profiling, which monitors and analyzes the changes in the size and shape of thousands of cells through imaging technology.
Human MSCs undergo morphological changes after being stimulated by growth factors, making the identification of these cells’ size and shape especially crucial. This is because FDA scientists have demonstrated that these morphological changes can predict the ability of the cells to develop specialized properties that might support their use in Regenerative Medicine clinical trials.
Although MSC-based therapies have not been made available yet, the ability to predict specific functions of MSCs in the lab is a significant advancement towards finally developing safe and effective treatment for patients. Until then, researchers must be certain that MSCs do not act independently, but ensure that they will work together to perform the same specific and predictable function.

H/T: FDA Voice
Global Stem Cells August 15, 2018
Tags:
Cellular Treatment
Stem Cell Research
Stem Cell Treatment
Categories:
Misc.
Aug
07
2018
A Stem Cell Treatment may help stroke recovery in patients with the method involving a single dose of millions of adult, bone-marrow-derived stem cells, a method which is observed to be safe and well-tolerated by the patients. The multicenter trial monitors stroke recovery even though it may not significantly improve their condition within the first three months, according to a research from Medical College of Georgia at Augusta University, reported by Science Daily.
The American Heart Association defines stroke as a leading cause of long-term disability and the
leading preventable cause of disability.
Results show that giving the Stem Cell Therapy early to patients within the first 36 hours after stroke symptoms appear may enhance physical recovery, reduce destructive inflammation as well as the risk for serious infections.
“There is solid evidence from our basic science work and now some indicators from this phase 2 patient trial that giving these stem cells can safely help dial back the body’s immune response to stroke injury that can ultimately further damage the brain and body,” said Dr. David C. Hess, stroke specialist and chairman of the Department of Neurology at the Medical College of Georgia at Augusta University.
The study was conducted at 33 centers in the United States and the United Kingdom from October 2011 to December 2015. It included 129 adult patients with moderately severe strokes. Some were given a dose of 400 million cells, then increased to 1,200 million cells for the majority of patients, whilst the remainder of the patients received placebo. The two groups, however, also underwent standard stroke therapies, including the clot-buster tPA and/or and endovascular procedure to retrieve the clot.
The trial was done within a timeframe of 36 hours and patients were followed for 90 days to a full year to study long term results. The result shows that a group that received Stem Cell Therapy and whose results are observed in a longer-term, rather than those under placebos, is more likely to see reduced disability and fewer infections.
The multipotent cells used in the treatment, called MultiStem, were developed by the international biotechnology company Athersys Inc., that funded the clinical trial. Doses were the largest ever given in a human cell therapy trial.
Dr. Hess said, “The cells are ‘off the shelf’ and ready to go. One donor of these cells provides hundreds of thousands of doses to patients.”
Dr. Hess explained that the cells work by modulating the body’s immune response which helps the brain heal
and remove debris from dead or damaged tissue. The researchers also found patients receiving cell therapy had lower blood levels of inflammatory signals, which prevent natural healing tendencies of the body.
Stroke also causes the spleen to shrink in size within the first hours after symptoms of stroke arise.
“Shrinkage that follows a stroke prompts it to quickly dump activated immune cells that can go to the brain and worsen inflammation and damage there,” Hess said. The spleen is an organ about four inches long located to the left of the stomach and is an important immune system regulator that filters blood and stores immune cells. Although, in the trial, the spleen was not examined, animal trials proved that there is a spleen shrinkage reduction with cell therapy and researchers hope to look more into this in future studies.

H/T: Science Daily
Global Stem Cells August 7, 2018 August 16, 2018
Tags:
Cellular Treatment
Stem Cell Research
Stem Cell Treatment
Categories:
Misc.
Jul
31
2018
Regenerative Medicine Goes to The Root Causes of Diseases
Regenerative Medicine is a type of stem cell treatment that attacks the root cause of diseases rather than just the symptom. The process involves taking a cell from a donor and putting them into a patient to treat a disease or injury. It can replace lost cells or organs or fix a problematic gene. However, as reported by Medical News Today, Regenerative Medicine needs to develop itself into mainstream medicine through better science and regulation as well as integrating with innovative manufacturing methods to make treatments affordable to the mass.
The Difference Between Regenerative Medicine and Traditional Drugs for Treatment
Regenerative Medicine aims to replace or repair human cells, or regenerate tissue or organs to restore normal function. It makes use of cells, biomaterials, and molecules to fix structures in the body that is malfunctioning. For example, if a person with type 1 diabetes wants to start producing insulin, the traditional way to treat a person with type 1 diabetes would be injecting insulin daily to keep blood sugar levels normal. With Regenerative Medicine, a patient can regenerate their own insulin-producing tissue called the islets of Langerhans, which eliminates the need for routine insulin rejection. While this treatment for type 1 diabetes is not yet possible, there are some areas of Regenerative Medicine that is used in medical practice today.
Methods of Regenerative Medicine
Cell therapy originated from the method of transfusion of the blood which is a common practice in clinics around the world. There was also the method of transplanting the bone marrow where patients with radiation damage or blood cancers can regenerate healthy blood cells using the donor’s bone marrow stem cells. Cell therapy using a patient’s own cells is also used for severe burn and injuries. Medical News Today also reported on a chip technology that can change one cell type into another and heal entire organs and another method of spray painting biomaterials onto damaged hearts using surgery.
Although there are many studies into Regenerative Medicine, the Food and Drug Administration (FDA) only approves 15 entries for cellular and gene therapy products
The Future of Regenerative Medicine
Although there are many breakthrough researches for Regenerative Medicine, medical treatment through this process is still scarce and a panel of FDA commissioners noted that there is a lack of progress in the field, with only a handful of breakthroughs have made it to patients. Despite the success of Regenerative Medicine studies, only a small number of diseases can be treated through this method. Prof. Giulio Cossu from the Division of Cell and Matrix Biology & Regenerative Medicine at the University of Manchester in the United Kingdom, said that complex diseases such as diabetes or heart will require more advanced approaches than what is available today.

H/T: Medical News Today
Global Stem Cells July 31, 2018
Tags:
Cellular Treatment
Stem Cell Research
Stem Cell Treatment
Categories:
Misc.
Jul
25
2018
Doctors found a major breakthrough in Stem Cell treatment for Multiple Sclerosis (MS), according to Telegraph. MS is a disease where the immune system stops functioning and instead, attacks nerve cells in the brain and spinal cord. Patients often cannot move, have blurred visions, and lose the sense of balance and the ability to talk.
The Stem Cell treatment is used in chemotherapy in which the immune system is deactivated for a short period of time and then resets again, as described by Telegraph. Patients were given a drug which would move stem cell from the bone marrow into the bloodstream, where they were removed from the body. A high dosage of chemotherapy was then used to kill all immune cells, before the patient’s stem cells were put back into the body to reset the immune system. A study conducted by Imperial College London discovered that 46 percent of patients who had been treated with stem cell transplantation were able to freeze the disease progression for as long as five years.
This treatment was also tested internationally with 100 patients from hospitals in Chicago, Sheffield, Stockholm, and Sao Paolo, according to BBC. They were either being treated with Stem Cell Treatment or the Conventional Drugs. According to the test results, there was only one relapse among 52 patients who had the stem cell treatment and 3 failed transplant treatment. In contrary, those who were given conventional drug treatment showed poorer results with 39 of 50 patients having a relapse within a year. Over three years, the treatment failed for 30 of them.
Besides slowing down disease progression, the Stem Cell treatment also reduces disability for people with MS. Louise Willmetts, 36, from Rotherham said to BBC that she was free from symptoms of MS since she was diagnosed in 2010 and described the experience as a miracle.
However, the researchers said that AHSCT comes with some risks. Since the chemotherapy deactivates the immune system for a short period of time, it can shut down disease fending mechanism during the time. Those who were treated also had relapsing-remitting MS (RRMS), which is common in people with multiple sclerosis (MS). There are many symptoms during RRMS which includes numbness and a tingling pain that runs down the spine when bending the neck.
Despite possible risks and relapses, the treatment gives hope to patients who are currently affected by multiple sclerosis (MS), considering there is no cure at the moment. Prof John Snowden, Director of blood and bone marrow transplantation at Sheffield’s Royal Hallamshire Hospital, told the BBC: “We are thrilled with the results – they are a game changer for patients with drug resistant and disabling multiple sclerosis.”

H/T: Telegraph
Global Stem Cells July 25, 2018 July 25, 2018
Tags:
Cellular Treatment
Multiple Sclerosis Research
Stem Cell Research
Stem Cell Treatment
Categories:
Multiple Sclerosis (MS)

Highlighted Treatable Conditions

Visual Impairment

Not Listed Medical Conditions

Tag: Cellular Treatment

What is Ataxia?

Spreading Awareness of Ataxia

Stem Cell Treatment for Ataxia at Unique Access Medical

About Amyotrophic Lateral Sclerosis:

Mesenchymal Stem Cells and Its Benefit in Stem Cell Therapy

The Problem with MSCs

Morphological Profiling to Predict Outcomes in MSCs

Regenerative Medicine Goes to The Root Causes of Diseases

The Difference Between Regenerative Medicine and Traditional Drugs for Treatment

Methods of Regenerative Medicine

The Future of Regenerative Medicine

Contact a Stem Cell Treatment Specialist Now!

Privacy Overview

Strictly Necessary Cookies

Cookie Policy